{
  "ticker": "LLY",
  "target_date": "2025-05-07",
  "actual_date": "2025-05-07",
  "collected_at": "2025-12-08T11:44:03.073143",
  "price": {
    "open": 776.06,
    "high": 779.87,
    "low": 767.86,
    "close": 772.2981567382812,
    "volume": 3807800,
    "change_1d_pct": 0.21,
    "change_7d_pct": -11.46,
    "change_30d_pct": -8.87
  },
  "technicals": {
    "rsi_14": 55.14,
    "sma_20": 803.66,
    "sma_50": 821.87,
    "macd": -0.152,
    "macd_signal": 4.42,
    "macd_histogram": -4.572,
    "bb_upper": 914.71,
    "bb_lower": 692.6,
    "price_vs_sma20_pct": -3.9,
    "price_vs_sma50_pct": -6.03,
    "volume_ratio": 0.83
  },
  "fundamentals": {
    "market_cap": 891405205504,
    "pe_ratio": 48.7195,
    "forward_pe": 43.88195,
    "price_to_book": 37.438442,
    "price_to_sales": 15.0018215,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.58,
    "pct_from_52w_low": 59.41
  },
  "macro": {
    "spy": {
      "price": 557.95,
      "change_1d_pct": 0.42,
      "change_7d_pct": 1.23
    },
    "vix": {
      "level": 23.55,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.28
    },
    "dollar_index": {
      "level": 99.61
    },
    "gold": {
      "price": 3381.4
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Hartford Growth Opportunities Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1746658320,
      "summary": "The Hartford Growth Opportunities Fund (I Share) underperformed the Russell 3000 Growth Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=b44bd256d23b79f849fd26897a02f4ddcc1e3a0037f6e7edba09e100f587ddc3"
    },
    {
      "headline": "Hartford Core Equity Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1746638580,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=628123fd0ae5f166c3eccd6e90f406a5962ccb18fc51660b756316ae1e3278ac"
    },
    {
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "source": "Yahoo",
      "datetime": 1746638247,
      "summary": "We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls\u2019 thesis on LLY. Eli Lilly and Company (LLY)\u2019s share was trading at $794.10 as of May 1st. LLY\u2019s trailing and forward P/E were 64.61 and 35.34 respectively according to Y",
      "url": "https://finnhub.io/api/news?id=6ff25f582d40ab50c6875b6dae05d2516e5d9f2e83c290240715d778ff9b926d"
    },
    {
      "headline": "Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO",
      "source": "Yahoo",
      "datetime": 1746636198,
      "summary": "Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.",
      "url": "https://finnhub.io/api/news?id=23a6e113969e3565f4292effd093360bebf762429295d1e06168754f7b7eb7ed"
    },
    {
      "headline": "Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up",
      "source": "Yahoo",
      "datetime": 1746628140,
      "summary": "NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.",
      "url": "https://finnhub.io/api/news?id=9e8c293485f904414ab2d9b6242375de494a37be0b6e75ce4f4ee12d808e7f8f"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746476222.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000134/xslF345X05/wk-form4_1746476222.xml"
    },
    {
      "form": "10-Q",
      "date": "2025-05-01",
      "description": "lly-20250331.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm"
    },
    {
      "form": "8-K",
      "date": "2025-05-01",
      "description": "lly-20250501.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000124/xslF345X05/wk-form4_1745353361.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353273.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000122/xslF345X05/wk-form4_1745353273.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}